Heidelberg Pharma AG is a biopharmaceutical company working in the field of oncology. The company is focused on the development of Antibody Drug Conjugates (ADCs) for the treatment of oncological diseases. Heidelberg Pharma's so-called ATACs are ADCs based on the ATAC technology that uses Amanitin as an active ingredient. The biological mechanism of action of the Amanitin toxin represents a new therapeutic principle.
This proprietary platform is being applied to develop the Company’s own therapeutic ATACs and third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. Further preclinical development candidates are HDP-102, a CD37 ATAC for Non-Hodgkin lymphoma and HDP-103, a PSMA ATAC for metastatic castration-resistant prostate cancer.
The company as well as its subsidiary Heidelberg Pharma Research GmbH is based in Ladenburg near Heidelberg in Germany. It was founded in September 1997 as Wilex Biotechnology GmbH in Munich and was changed to WILEX AG in 2000. In 2011, the subsidiary Heidelberg Pharma Research GmbH was acquired and after a restructuring, the registered office of WILEX AG was moved from Munich to Ladenburg and the name of the Company was changed to Heidelberg Pharma AG. The subsidiary Heidelberg Pharma GmbH is now named Heidelberg Pharma Research GmbH. Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange in the Regulated Market / Prime Standard.
The Company has out-licensed product candidates from Wilex's legacy portfolio (upamostat and girentuximab) to partners. For further information, please go to portfolio or technologies.